<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37069477</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Significance of the weighted complement domain of the EULAR/ACR classification criteria in juvenile onset systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>756</StartPage><EndPage>762</EndPage><MedlinePgn>756-762</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231171343</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We aimed to compare the clinical and laboratory characteristics of patients with SLE according to the weighted complement status of the EULAR/ACR criteria and investigate whether different weighting of the complement status at disease onset is associated with outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients diagnosed with juvenile onset SLE who fulfilled the 2019 EULAR/ACR classification criteria were retrospectively analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 43 patients included, hypocomplementemia was observed in 37 (86%), mostly with a low level of both complement C3 (C3) and complement C4 (C4) (53.5%). In patients with low levels of both C3 and C4, more common cutaneous (65.2% vs 28.6%, <i>p</i>: 0.045), musculoskeletal involvement (78.3% vs 42.9%, <i>p</i>: 0.039), autoimmune hemolytic anemia (52.2% vs 14.3%, <i>p</i>: 0.035), positive anti-dsDNA (65.2% vs 21.4%, <i>p</i>: 0.017) and anti-Sm antibodies (60.9% vs 21.4%, <i>p</i>: 0.04) were observed. In addition these patients had higher scores from the 2019 EULAR/ACR classification criteria (26 vs 15.5, <i>p</i>: &lt; 0.0001). Remission and flare rates, and SLE associated damage were not differed according to the complement status in patients with hypocomplementemia.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Observation of more frequent clinical and serological activity with higher total scores from the EULAR/ACR classification criteria supported the higher scoring of patients with low C3 and C4 in the weighted criteria. However, since significant number of patients did not exhibit low complement C4, and the frequency of kidney involvement did not differ according to the weighted complement status, complement C3 might be suggested as a more important diagnostic tool in patients with juvenile onset SLE. Also, weighted complement status at onset did not seem to affect the disease outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kisaoglu</LastName><ForeName>Hakan</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-1095-3222</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Pediatric Rheumatology, Karadeniz Technical University, Trabzon, Turkey.</Affiliation><Identifier Source="RINGGOLD">64255</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baba</LastName><ForeName>Ozge</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Pediatric Rheumatology, Karadeniz Technical University, Trabzon, Turkey.</Affiliation><Identifier Source="RINGGOLD">64255</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalyoncu</LastName><ForeName>Mukaddes</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Pediatric Rheumatology, Karadeniz Technical University, Trabzon, Turkey.</Affiliation><Identifier Source="RINGGOLD">64255</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003176">Complement C3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003181">Complement C4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003176" MajorTopicYN="N">Complement C3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003181" MajorTopicYN="N">Complement C4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Damage</Keyword><Keyword MajorTopicYN="N">EULAR/ACR classification criteria</Keyword><Keyword MajorTopicYN="N">hematologic involvement</Keyword><Keyword MajorTopicYN="N">hypocomplementemia</Keyword><Keyword MajorTopicYN="N">juvenile SLE</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>17</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37069477</ArticleId><ArticleId IdType="doi">10.1177/09612033231171343</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>